Balyasny Asset Management
ESPR

Balyasny Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Balyasny Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-100,000
Closed -$3.72M – 1429
2020
Q3 		$3.72M Buy
+100,000
New +$3.96M 0.03% 684
2020
Q2 		– Sell
-50,000
Closed -$1.58M – 1229
2020
Q1 		$1.58M Sell
50,000
-75,000
-60% -$3.96M 0.02% 660
2019
Q4 		$7.45M Buy
+125,000
New +$5.62M 0.04% 501
2019
Q1 		– Sell
-108,000
Closed -$4.97M – 1453
2018
Q4 		$4.97M Buy
+108,000
New +$5.2M 0.04% 507
2017
Q3 		– Sell
-140,000
Closed -$6.48M – 1929
2017
Q2 		$6.48M Buy
+140,000
New +$5.15M 0.03% 680

Other funds holding ESPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Balyasny Asset Management's ESPR Position: Q4 2025 in Review

Balyasny Asset Management sold out of Esperion Therapeutics (ESPR) in Q4 2025, closing a stake of 115,624 shares — an estimated $306K sold.

Balyasny Asset Management first reported a position in ESPR in Q1 2017 and held it in 20 quarters. The position peaked at $26.5M in Q4 2017. 200 funds tracked by Wall St. Rank hold ESPR as of Q4 2025.

  • Balyasny Asset Management reported no remaining Esperion Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 115,624 Esperion Therapeutics shares in Q4 2025, an estimated $306K.
  • Balyasny Asset Management first reported a position in Esperion Therapeutics in Q1 2017 and held it in 20 quarters.
  • Balyasny Asset Management's Esperion Therapeutics position peaked at $26.5M in Q4 2017.
  • 200 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.